Immunogenicity of lipid sustained release implants containing imiquimod, α-galactosylceramide, or Quil-A

Pharmazie

Volumn 63, Issue 9, 2008, Pages 686-692

  Myschik, J ^a   McBurney, W T ^a   Hennessy, T ^a   Rades, T ^a   Hook, Sarah ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; IMIQUIMOD; IMMUNOGLOBULIN G ANTIBODY; OVALBUMIN; QUIL A;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CONTROLLED STUDY; IMMUNOGENICITY; MOUSE; NONHUMAN; SUSTAINED RELEASE FORMULATION;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG IMPLANTS; EPITOPES; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; IMMUNIZATION; IMMUNOGLOBULIN G; LIPIDS; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; ORGANISMS, GENETICALLY MODIFIED; OVALBUMIN; SAPONINS; VACCINES;

EID: 52649118645     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.8072     Document Type: Article

References (54)

1. Akira S (2003) Mammalian Toll-like receptors. Curr Opin Immunol 15: 5-11.
2. Barr IG, Sjolander A, Cox JC (1998) ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 32: 247-271.
3. Behboudi S, Morein B, Villacres-Eriksson MC (1999) Quillaja Saponin Formulations that Stimulate Proinflammatory Cytokines Elicit a Potent Acquired Cell-Mediated Immunity. Scand J Immunol 50: 371-377.
4. Borg NA, Wun KS, Kjer-Nielsen L, Wilce MCJ, Pellicci DG, Koh R, Besra GS, Bharadwaj M, Godfrey DI, McCluskey J, Rossjohn J (2007) CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448 (7149): 44-49.
5. Bramwell VW, Perrie Y (2005) Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst 22: 151-214.
6. Bratkiewicz RR (2006) CD1d Ligands: The Good, the Bad, and the Ugly. J Immunol 177: 769-775.
7. Burstein HJ, Shea CM, Abbas AK (1992) Aqueous antigens induce in vivo tolerance selectively in IL-2 and DFN-y producing (Th1) cells. J Immunol 148: 3687-3691.
8. Chung Y, Chang W-S, Kim S, Kang C-Y (2004) NKT cell ligand α-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur J Immunol 34: 2471-2479.
9. De Silva AD, Park JJ, Matsuki N, Stanic AK, Bratkiewicz RR, Medof ME, Joyce S (2002) Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J Immunol 168: 723-733.
10. Demana PH, Davies NM, Hook S, Rades T (2005) Quil A-lipid powder formulations releasing ISCOMs and related colloidal structures upon hydration. J Control Release 103: 45-59.
11. Fujii S-i, Shimizu K, Smith C, Bonifaz L, Steinman RM (2003) Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein. J Exp Med 198: 267-279.
12. Giabbai B, Sidobre S, Crispin MDM, Sanchez-Ruìz Y, Bachi A, Kronenberg M, Wilson IA, Degano M (2005) Crystal Structure of Mouse CD1d Bound to the Self Ligand Phosphatidylcholine: A Molecular Basis for NKT Cell Activation. J Immunol 175: 977-984.
13. Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BME, Scheper RJ, van der Vliet HJJ, van den Eertwegh AJM, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM (2002) A Phase I Study of the Natural Killer T-Cell Ligand {alpha}-Galactosylceramide (KRN7000) in Patients with Solid Tumors. Clin Cancer Res 8: 3702-3709.
14. Gupta AK, Cherman AM, Tyring SK (2004) Viral and Nonviral Uses of Imiquimod: A Review. J Cutan Med Surg 8: 338-352.
15. Gupta RK (1998) Aluminium compounds as vaccine adjuvants. Adv Drag Deliv Rev 32: 155-172.
16. Guse C, Koennings S, Kreye F, Siepmann F, Goepferich A, Siepmann J (2006a) Drug release from lipid-based implants: Elucidation of the underlying mass transport mechanisms. Int J Pharm 314: 137-144.
17. Guse C, Koennings S, Maschke A, Hacker M, Becker C, Schreiner S, Blunk T, Spruss T, Goepferich A (2006b) Biocompatibility and erosion behaviour of implants made of triglycerides and blends with cholesterol and phospholipids. Int J Pharm 314: 153-160.
18. Hayakawa Y, Godfrey DI, Smyth MJ (2004) α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application. Curr Med Chem 11: 241-252.
19. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3: 196-200.
20. + T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells. J Immunol 171: 5140-5147.
21. Herrmann S, Winter G, Mohl S, Siepmann F, Siepmann J (2007) Mechanisms controlling protein release from lipidic implants: Effects of PEG addition. J Control Release 118: 161-168.
22. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T (2005) A Phase I Study of {alpha}-Galactosylceramide (KRN7000)-Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer. Clin Cancer Res 11: 1910-1917.
23. Johansson M, Lövgren-Bengtsson K (1999) Iscoms wim different quillaja saponin components differ in their immunomodulating activities. Vaccine 17: 2894-2900.
24. Johnston D, Bystryn J-C (2006) Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 24: 1958-1965.
25. Johnston D, Zaidi B, Bystryn J-C (2007) TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 56: 1133-1141.
26. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M (1997) CD1d-Restricted and TCR-Mediated Activation of V{alpha}14 NKT Cells by Glycosylceramides. Science 278: 1626-1629.
27. Kensil CR (1996) Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13: 1-55.
28. Kensil CR, Patel U, Lennick M, Marciani D (1991) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina Cortex. J Immunol 146: 431-437.
29. Kersten GF, Spiekstra A, Beuvery EC, Crommelin DJA (1991) On the structure of immune-stimulating saponin-lipid complexes (iscoms). Biochim Biophys Acta 1062: 165-171.
30. Khan MZI, Tucker IG, Opdebeeck JP (1991) Cholesterol and lecithin implants for sustained release of antigen: release and erosion in vitro, and antibody response in mice. Int J Pharm 76: 161-170.
31. Khan MZI, Tucker IG, Opdebeeck JP (1993) Evaluation of cholesterol-lecithin implants for sustained delivery of antigen: release in vivo and single-step immunisation of mice. Int J Pharm 90: 255-262.
32. Koennings S, Tessmar J, Blunk T, Goepferich A (2007) Confocal Microscopy for the Elucidation of Mass Transport Mechanisms Involved in Protein Release from Lipid-based Matrices. Pharm Res 24: 1325-1335.
33. Lang GA, Exley MA, Lang ML (2006) The CD1d-binding glycolipid α-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology 119: 116-125.
34. Lawton AP, Kronenberg M (2004) The Third Way: Progress on pathways of antigen processing and presentation by CD1. Immunol Cell Biol 82: 295-306.
35. Lee A, Farrand KJ, Dickgreber N, Hayman CM, Jurs S, Hermans IF, Painter GF (2006) Novel synthesis of [alpha]-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity. Carbohydr Res 341: 2785-2798.
36. Lendemans DG (2006) Novel cationic preparations of ISCOMs as vaccine carriers. PhD thesis, University of Otago, Dunedin, New Zealand.
37. Marciani DJ (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8: 934-943.
38. Mohl S, Winter G (2004) Continuous release of rh-interferon [alpha]-2a from triglyceride matrices. J Control Release 97: 67-78.
39. Naidenko OV, Koezuka Y, Kronenberg M (2000) CD1-mediated antigen presentation of glycosphingolipids. Microbes Infect 2: 621-631.
40. Natori T, Morita M, Akimoto K, Koezuka Y (1994) Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus. Tetrahedron 50: 2771-2784.
41. Parekh VV, Singh AK, Wilson MT, Olivares-Villagomez D, Bezbradica JS, Inazawa H, Ehara H, Sakai T, Serizawa I, Wu L, Wang C-R, Joyce S, Van Kaer L (2004) Quantitative and Qualitative Differences in the In Vivo Response of NKT Cells to Distinct {alpha}- and {beta}-Anomeric Glycolipids. J Immunol 173: 3693-3706.
42. Rönnberg B, Fekadu M, Morein B (1995) Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 13: 1375-1382.
43. Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M (2006) Immune response modifiers - mode of action. Exp Dermatol 15: 331-341.
44. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, Mathew B, Schmidt RR, Lunt SJ, Williams KJ, Stratford IJ, Harris AL, Cerundolo V (2004) Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114: 1800-1811.
45. Soltysik S, Wu J-Y, Recchia J, Wheeler DA, Newman MJ, Coughlin RT, Kensil CR (1995) Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13: 1403-1410.
46. Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27: 571-577
47. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP (2004) Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunomerapeutic delivery. Vaccine 22: 1799-1809
48. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ (2000) The Immune Response Modifiers Imiquimod and R-848 Are Potent Activators of B Lymphocytes. Cell Immunol 203: 55-65.
49. Tsuji M (2006) Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol Life Sci 63: 1889-1898.
50. Vogelhuber W, Magni E, Mouro M, Spruß T, Guse C, Gazzaniga A, Goepferich A (2003) Monolithic triglyceride matrices: a controlled-release system for proteins. Pharm Dev Technol 8: 71-79.
51. Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, Reiter MJ, Vasilakos JP, Tomai MA (1999) Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod. Cell Immunol 191: 10-19.
52. Walduck AK, Opdebeeck JP, Benson HE, Prankerd R (1998) Biodegradable implants for the delivery of veterinary vaccines: design, manufacture and antibody response in sheep. J Control Release 51: 269-280
53. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL (2005) TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 23: 5263-5270.
54. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kuendig T, Hengartner H (1997) Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156: 199-209.